glp-1 als Frontiers Glucagon-like peptide-1 (GLP-1) receptor agonists
Description
35 Within the kidneys, there are 2 salient SGLTs: SGLT-1 and SGLT-2
Who Should (and Shouldn't) Take GLP-1 Medications
The nasal spray format is praised for enabling measured, repeatable dosing, which supports precision in study design
Sexton and co-workers developed a series of quercetin-like flavonoids ( 17 ) with positive allosteric modulator activity on GLP-1R
This finding is particularly significant as it demonstrates that the cardiovascular benefits of GLP-1 agonists extend beyond their glucose-lowering effects to encompass direct cardiovascular protection in obesity
